Hodgkin's Lymphoma in Crohn's Disease Treated with Infliximab

Overview

Journal GE Port J Gastroenterol

Specialty Gastroenterology

Date 2017 Dec 20

PMID 29255769

Citations 3

Authors

Diana Carvalho

Pedro Russo

Carlos Bernardes

Joana Saiote

Goncalo Ramos

Luis Mascarenhas

Nuno Borges

Jaime Ramos

Affiliations

Soon will be listed here.

Abstract

Introduction: Lymphoproliferative disorders, particularly non-Hodgkin's and Hodgkin's lymphomas, are rare in patients with inflammatory bowel diseases. The use of thiopurines and infection by Epstein-Barr virus are well-known cofactors that can raise its prevalence. Other risk factors such as disease activity and biological treatment are the subject of discussion, without enough data in the literature to confirm a potential association.

Methods: We report a case of Hodgkin's lymphoma in a patient who had been treated with azathioprine and was on long-term monotherapy with infliximab.

Conclusions: We stress the importance of recognizing the possible occurrence of a lymphoproliferative disorder in association with anti-tumor necrosis factor-α therapy.

Citing Articles

Medical radiation exposure in inflammatory bowel disease: an updated meta-analysis.

Lu C, Yao X, Yu M, He X BMC Gastroenterol. 2024; 24(1):173.

PMID: 38762503 PMC: 11102164. DOI: 10.1186/s12876-024-03264-1.

The Complex Relationship between Mechanisms Underlying Inflammatory Bowel Disease, Its Treatment, and the Risk of Lymphomas: A Comprehensive Review.

Stasik K, Filip R Int J Mol Sci. 2024; 25(8).

PMID: 38673824 PMC: 11049907. DOI: 10.3390/ijms25084241.

Crohn's disease with infliximab treatment complicated by rapidly progressing colorectal cancer: A case report.

Xiao L, Sun L, Zhao K, Pan Y World J Gastrointest Oncol. 2021; 13(4):305-311.

PMID: 33889281 PMC: 8040059. DOI: 10.4251/wjgo.v13.i4.305.

References

Coghill A, Hildesheim A . Epstein-Barr virus antibodies and the risk of associated malignancies: review of the literature. Am J Epidemiol. 2014; 180(7):687-95. PMC: 4271109. DOI: 10.1093/aje/kwu176. View

Annese V, Beaugerie L, Egan L, Biancone L, Bolling C, Brandts C . European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies. J Crohns Colitis. 2015; 9(11):945-65. DOI: 10.1093/ecco-jcc/jjv141. View

Chiorean M, Pokhrel B, Adabala J, Helper D, Johnson C, Juliar B . Incidence and risk factors for lymphoma in a single-center inflammatory bowel disease population. Dig Dis Sci. 2010; 56(5):1489-95. DOI: 10.1007/s10620-010-1430-z. View

Nyboe Andersen N, Pasternak B, Basit S, Andersson M, Svanstrom H, Caspersen S . Association between tumor necrosis factor-α antagonists and risk of cancer in patients with inflammatory bowel disease. JAMA. 2014; 311(23):2406-13. DOI: 10.1001/jama.2014.5613. View

Jess T, Horvath-Puho E, Fallingborg J, Rasmussen H, Jacobsen B . Cancer risk in inflammatory bowel disease according to patient phenotype and treatment: a Danish population-based cohort study. Am J Gastroenterol. 2013; 108(12):1869-76. DOI: 10.1038/ajg.2013.249. View

Dahhan T, Al Kahtani K, Bakshi N, Abouzied M, Helmy A . Extra-intestinal Hodgkin's lymphoma in a Crohn's disease patient on long-term azathioprine and infliximab therapy. Trop Gastroenterol. 2010; 31(1):51-3. View

Rodriguez A, Kerner J, Luna-Fineman S, Berry G . Hodgkin lymphoma following adalimumab for the treatment of Crohn's disease in an adolescent. Dig Dis Sci. 2014; 59(10):2403-5. DOI: 10.1007/s10620-014-3191-6. View

Mo N, Muthu S, OSullivan M . Regression of lymphoma after withdrawal of infliximab alone in an infliximab/methotrexate-treated RA patient. Rheumatology (Oxford). 2010; 50(4):808-10. DOI: 10.1093/rheumatology/keq417. View

Cassaday R, Malik J, Chang J . Regression of Hodgkin lymphoma after discontinuation of a tumor necrosis factor inhibitor for Crohn's disease: a case report and review of the literature. Clin Lymphoma Myeloma Leuk. 2011; 11(3):289-92. DOI: 10.1016/j.clml.2011.03.018. View

10.

Sifuentes H, Kane S . Monitoring for Extra-Intestinal Cancers in IBD. Curr Gastroenterol Rep. 2015; 17(11):42. DOI: 10.1007/s11894-015-0467-8. View

11.

Magro F, Peyrin-Biroulet L, Sokol H, Aldeger X, Costa A, Higgins P . Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III). J Crohns Colitis. 2013; 8(1):31-44. DOI: 10.1016/j.crohns.2013.04.006. View

12.

Beaugerie L, Brousse N, Bouvier A, Colombel J, Lemann M, Cosnes J . Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009; 374(9701):1617-25. DOI: 10.1016/S0140-6736(09)61302-7. View

13.

Pedersen N, Duricova D, Elkjaer M, Gamborg M, Munkholm P, Jess T . Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies. Am J Gastroenterol. 2010; 105(7):1480-7. DOI: 10.1038/ajg.2009.760. View

14.

Vockerodt M, Yap L, Shannon-Lowe C, Curley H, Wei W, Vrzalikova K . The Epstein-Barr virus and the pathogenesis of lymphoma. J Pathol. 2014; 235(2):312-22. DOI: 10.1002/path.4459. View